Aptargroup (ATR) beats Q2 2026 estimates with revenue topping $1 billion

Aptargroup posted Q2 2026 earnings per share of $1.42, topping the consensus estimate of roughly $1.35 by about 5%. Revenue came in at $1.03 billion, clearing the $1.01 billion estimate by about 1.5% and marking the first time in the company's recent quarterly run that sales have crossed the billion-dollar threshold. That compares to $910 million in Q2 2024, reflecting a meaningful step up in the business over the past year.

Two drivers stood out in the quarter: double-digit growth in the beauty segment and surging demand for GLP-1 drug delivery systems. The GLP-1 tailwind reflects broader market appetite for injectable weight-loss and diabetes treatments, where Aptargroup supplies the dispensing and delivery components that drugmakers depend on. Together, those forces helped lift revenue well above the levels the company was posting through the back half of 2024 and into early 2025.

The strong results land as Aptargroup navigates a leadership transition, with new management set to take over in September. Investors will be watching to see whether the momentum in pharma delivery and beauty holds under incoming leadership, and whether quarterly revenue can sustain above the $1 billion mark.